Contineum Therapeutics, Inc. Class A Common Stock (CTNM)
Automate Your Wheel Strategy on CTNM
With Tiblio's Option Bot, you can configure your own wheel strategy including CTNM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CTNM
- Rev/Share 0.0
- Book/Share 6.4189
- PB 1.4347
- Debt/Equity 0.0304
- CurrentRatio 29.072
- ROIC 0.1817
- MktCap 336404770.0
- FreeCF/Share -1.8789
- PFCF -6.368
- PE -4.3598
- Debt/Assets 0.0288
- DivYield 0
- ROE -0.3233
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 3
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | CTNM | Morgan Stanley | Overweight | Equal Weight | -- | $14 | Jan. 8, 2026 |
| Initiation | CTNM | Leerink Partners | -- | Outperform | -- | $22 | Nov. 13, 2025 |
| Initiation | CTNM | Leerink Partners | -- | Outperform | -- | $20 | Sept. 25, 2025 |
| Initiation | CTNM | William Blair | -- | Outperform | -- | -- | June 20, 2025 |
| Initiation | CTNM | Robert W. Baird | -- | Outperform | -- | $32 | Oct. 22, 2024 |
News
Contineum Therapeutics, Inc. (CTNM) Upgraded to Buy: What Does It Mean for the Stock?
Published: December 31, 2025 by: Zacks Investment Research
Sentiment: Positive
Contineum Therapeutics, Inc. (CTNM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
Wall Street Analysts See a 91.49% Upside in Contineum Therapeutics, Inc. (CTNM): Can the Stock Really Move This High?
Published: December 31, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 91.5% in Contineum Therapeutics, Inc. (CTNM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
Contineum Therapeutics' Multiple Sclerosis Trial Disappoints, But Analyst Sees Other Assets Driving Value
Published: November 21, 2025 by: Benzinga
Sentiment: Negative
Contineum Therapeutics, Inc. (NASDAQ: CTNM) on Thursday shared topline data from its Phase 2 VISTA trial of PIPE-307, an M1 receptor antagonist for relapsing-remitting multiple sclerosis (RRMS).
Read More
Wall Street Analysts Think Contineum Therapeutics, Inc. (CTNM) Could Surge 235.81%: Read This Before Placing a Bet
Published: August 08, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 235.8% in Contineum Therapeutics, Inc. (CTNM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
About Contineum Therapeutics, Inc. Class A Common Stock (CTNM)
- IPO Date 2024-04-05
- Website https://www.contineum-tx.com
- Industry Biotechnology
- CEO Carmine N. Stengone
- Employees 41